Denali Therapeutics (NASDAQ:DNLI – Get Free Report) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Denali Therapeutics to announce earnings of ($0.5371) per share and revenue of $2.1540 million for the quarter. Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. Get Denali Therapeutics alerts:Denali Therapeutics Price PerformanceShares of DNLI opened at $23.85 on Thursday. Denali Therapeutics has a fifty-two week low of $12.58 and a fifty-two week high of $27.30.